Related Experiment Videos
Insights
Carvedilol, a beta-blocker for heart failure, showed reduced mortality in one large trial but not another. Its role in heart failure treatment requires further definition despite manageable side effects.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Carvedilol is the first beta-blocker approved for heart failure treatment.
- Initial studies showed hemodynamic improvements but had limited follow-up duration.
Purpose of the Study:
- To evaluate the efficacy and safety of carvedilol in heart failure patients.
- To assess the impact of carvedilol on mortality and symptom-based criteria.
Main Methods:
- Three initial studies with 156 patients, limited to 16-week follow-up.
- One large placebo-controlled, double-blind trial with 1094 patients.
- A second trial involving 415 patients with a 19-month average follow-up.
Main Results:
- A significant reduction in overall mortality (4.6% absolute) was observed in the large trial after 6.5 months.
- This mortality benefit was not replicated in the second trial with longer follow-up.
- Results regarding symptom improvement were conflicting; adverse effects were minor with gradual introduction.
Conclusions:
- Carvedilol demonstrated a mortality benefit in one large trial, but findings were inconsistent across studies.
- The precise role of carvedilol in heart failure management remains to be definitively established.
- Gradual titration appears to minimize adverse effects like malaise.
Abstract:
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was initially documented in three methodologically sound studies involving 156 patients. Follow up was limited to 16 weeks. A placebo-controlled, double-blind trial involving 1094 patients showed beneficial effects on overall mortality of 4.6% in absolute terms after a median follow up of 6.5 months. This benefit was not found in another trial involving 415 patients followed on average for 19 months. Results for symptom-based criteria conflict. When treatment is introduced very gradually, adverse effects (malaise) seem to be minor and infrequent. Carvedilol's place in the treatment of heart failure is not yet precisely documented.